257 related articles for article (PubMed ID: 15969882)
1. Variability of fine particle dose and lung deposition of budesonide delivered through two multidose dry powder inhalers.
Munzel U; Marschall K; Fyrnys B; Wedel M
Curr Med Res Opin; 2005 Jun; 21(6):827-33. PubMed ID: 15969882
[TBL] [Abstract][Full Text] [Related]
2. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
[TBL] [Abstract][Full Text] [Related]
3. Scintigraphic comparison of budesonide deposition from two dry powder inhalers.
Newman SP; Pitcairn GR; Hirst PH; Bacon RE; O'Keefe E; Reiners M; Hermann R
Eur Respir J; 2000 Jul; 16(1):178-83. PubMed ID: 10933104
[TBL] [Abstract][Full Text] [Related]
4. Equivalent lung deposition of budesonide in vivo: a comparison of dry powder inhalers using a pharmacokinetic method.
Lähelmä S; Kirjavainen M; Kela M; Herttuainen J; Vahteristo M; Silvasti M; Ranki-Pesonen M
Br J Clin Pharmacol; 2005 Feb; 59(2):167-73. PubMed ID: 15676038
[TBL] [Abstract][Full Text] [Related]
5. Novolizer: how does it fit into inhalation therapy?
Magnussen H
Curr Med Res Opin; 2005; 21 Suppl 4():S39-46; discussion S47. PubMed ID: 16138944
[TBL] [Abstract][Full Text] [Related]
6. Pharmacoscintigraphic evaluation of lipid dry powder budesonide formulations for inhalation.
Sebti T; Pilcer G; Van Gansbeke B; Goldman S; Michils A; Vanderbist F; Amighi K
Eur J Pharm Biopharm; 2006 Aug; 64(1):26-32. PubMed ID: 16697169
[TBL] [Abstract][Full Text] [Related]
7. Comparative in vitro performance evaluation of the Novopulmon 200 Novolizer and Budesonid-ratiopharm Jethaler: two novel budesonide dry powder inhalers.
de Boer AH; Gjaltema D; Hagedoorn P; Frijlink HW
Pharmazie; 2004 Sep; 59(9):692-9. PubMed ID: 15497751
[TBL] [Abstract][Full Text] [Related]
8. Air classifier technology (ACT) in dry powder inhalation Part 3. Design and development of an air classifier family for the Novolizer multi-dose dry powder inhaler.
de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
Int J Pharm; 2006 Mar; 310(1-2):72-80. PubMed ID: 16442248
[TBL] [Abstract][Full Text] [Related]
9. Emitted dose estimates from Seretide Diskus and Symbicort Turbuhaler following inhalation by severe asthmatics.
Tarsin WY; Pearson SB; Assi KH; Chrystyn H
Int J Pharm; 2006 Jun; 316(1-2):131-7. PubMed ID: 16584855
[TBL] [Abstract][Full Text] [Related]
10. Stability and performance characteristics of a budesonide powder for inhalation with a novel dry powder inhaler device.
Fyrnys B; Stang N; Wolf-Heuss E
Curr Opin Pulm Med; 2001 Apr; 7 Suppl 1():S7-11. PubMed ID: 11385814
[TBL] [Abstract][Full Text] [Related]
11. Systemic availability and lung deposition of budesonide via three different nebulizers in adults.
Dahlström K; Thorsson L; Larsson P; Nikander K
Ann Allergy Asthma Immunol; 2003 Feb; 90(2):226-32. PubMed ID: 12602671
[TBL] [Abstract][Full Text] [Related]
12. Gamma scintigraphic evaluation of a novel budesonide dry powder inhaler using a validated radiolabeling technique.
Warren S; Taylor G; Smith J; Buck H; Parry-Billings M
J Aerosol Med; 2002; 15(1):15-25. PubMed ID: 12006142
[TBL] [Abstract][Full Text] [Related]
13. Do all dry powder inhalers show the same pharmaceutical performance?
Taylor A; Gustafsson P
Int J Clin Pract Suppl; 2005 Dec; (149):7-12. PubMed ID: 16279997
[TBL] [Abstract][Full Text] [Related]
14. An in vivo and in vitro comparison of two powder inhalers following storage at hot/humid conditions.
Borgström L; Asking L; Lipniunas P
J Aerosol Med; 2005; 18(3):304-10. PubMed ID: 16181005
[TBL] [Abstract][Full Text] [Related]
15. Idealhalers or realhalers? A comparison of Diskus and Turbuhaler.
Borgström L; Asking L; Thorsson L
Int J Clin Pract; 2005 Dec; 59(12):1488-95. PubMed ID: 16351685
[TBL] [Abstract][Full Text] [Related]
16. Scintigraphic evaluation of lung deposition with a novel inhaler device.
Newman SP; Hirst PH; Pitcairn GR
Curr Opin Pulm Med; 2001 Apr; 7 Suppl 1():S12-4. PubMed ID: 11385810
[TBL] [Abstract][Full Text] [Related]
17. A 12-week, multicenter, randomized, partially blinded, active-controlled, parallel-group study of budesonide inhalation suspension in adolescents and adults with moderate to severe persistent asthma previously receiving inhaled corticosteroids with a metered-dose or dry powder inhaler.
Murphy K; Noonan M; Silkoff PE; Uryniak T
Clin Ther; 2007 Jun; 29(6):1013-26. PubMed ID: 17692718
[TBL] [Abstract][Full Text] [Related]
18. Lung deposition of budesonide from the novel dry powder inhaler Airmax.
Hirst RH; Newman SR; Clark DA; Hertog MG
Respir Med; 2002 Jun; 96(6):389-96. PubMed ID: 12117037
[TBL] [Abstract][Full Text] [Related]
19. In-vitro characterisation of metered dose inhaler versus dry powder inhaler glucocorticoid products: influence of inspiratory flow rates.
Feddah MR; Brown KF; Gipps EM; Davies NM
J Pharm Pharm Sci; 2000; 3(3):318-24. PubMed ID: 11177650
[TBL] [Abstract][Full Text] [Related]
20. Factors guiding the choice of delivery device for inhaled corticosteroids in the long-term management of stable asthma and COPD: focus on budesonide.
Thorsson L; Geller D
Respir Med; 2005 Jul; 99(7):836-49. PubMed ID: 15939245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
